243 related articles for article (PubMed ID: 29093347)
1. Comparative Utility of Atypical Antipsychotics for the Treatment of Psychosis in Parkinson's Disease: A Systematic Review and Bayesian Network Meta-analysis.
Iketani R; Kawasaki Y; Yamada H
Biol Pharm Bull; 2017; 40(11):1976-1982. PubMed ID: 29093347
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: A systematic review and Bayesian network meta-analysis.
Iketani R; Furushima D; Imai S; Yamada H
Parkinsonism Relat Disord; 2020 Sep; 78():82-90. PubMed ID: 32755800
[TBL] [Abstract][Full Text] [Related]
3. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis.
Yunusa I; Rashid N; Seyedin R; Paratane D; Rajagopalan K
J Geriatr Psychiatry Neurol; 2023 Sep; 36(5):417-432. PubMed ID: 36720473
[TBL] [Abstract][Full Text] [Related]
5. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Wilby KJ; Johnson EG; Johnson HE; Ensom MHH
Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039
[TBL] [Abstract][Full Text] [Related]
6. Treatment of psychosis in Parkinson's disease: safety considerations.
Fernandez HH; Trieschmann ME; Friedman JH
Drug Saf; 2003; 26(9):643-59. PubMed ID: 12814332
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Ballard C; Waite J
Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
[TBL] [Abstract][Full Text] [Related]
8. Clozapine and risperidone treatment of psychosis in Parkinson's disease.
Ellis T; Cudkowicz ME; Sexton PM; Growdon JH
J Neuropsychiatry Clin Neurosci; 2000; 12(3):364-9. PubMed ID: 10956570
[TBL] [Abstract][Full Text] [Related]
9. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease.
Friedman JH; Factor SA
Mov Disord; 2000 Mar; 15(2):201-11. PubMed ID: 10752567
[TBL] [Abstract][Full Text] [Related]
10. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis.
Morgante L; Epifanio A; Spina E; Zappia M; Di Rosa AE; Marconi R; Basile G; Di Raimondo G; La Spina P; Quattrone A
Clin Neuropharmacol; 2004; 27(4):153-6. PubMed ID: 15319699
[TBL] [Abstract][Full Text] [Related]
11. Second-generation antipsychotics for Parkinson's disease psychosis: A systematic review and network meta-analysis.
Srisurapanont M; Suradom C; Suttajit S; Kongsaengdao S; Maneeton B
Gen Hosp Psychiatry; 2024; 87():124-133. PubMed ID: 38412585
[TBL] [Abstract][Full Text] [Related]
12. Atypical antipsychotic drugs in the treatment of Parkinson's disease.
Friedman JH
J Pharm Pract; 2011 Dec; 24(6):534-40. PubMed ID: 22095576
[TBL] [Abstract][Full Text] [Related]
13. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis.
Yunusa I; Alsumali A; Garba AE; Regestein QR; Eguale T
JAMA Netw Open; 2019 Mar; 2(3):e190828. PubMed ID: 30901041
[TBL] [Abstract][Full Text] [Related]
15. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis.
Frieling H; Hillemacher T; Ziegenbein M; Neundörfer B; Bleich S
Eur Neuropsychopharmacol; 2007 Feb; 17(3):165-71. PubMed ID: 17070675
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
[TBL] [Abstract][Full Text] [Related]
17. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.
Fernandez HH; Friedman JH; Jacques C; Rosenfeld M
Mov Disord; 1999 May; 14(3):484-7. PubMed ID: 10348474
[TBL] [Abstract][Full Text] [Related]
18. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
19. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial.
Pintor L; Valldeoriola F; Baillés E; Martí MJ; Muñiz A; Tolosa E
Clin Neuropharmacol; 2012; 35(2):61-6. PubMed ID: 22388466
[TBL] [Abstract][Full Text] [Related]
20. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
Juncos JL; Roberts VJ; Evatt ML; Jewart RD; Wood CD; Potter LS; Jou HC; Yeung PP
Mov Disord; 2004 Jan; 19(1):29-35. PubMed ID: 14743357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
